Zimmer Biomet reported a solid fourth quarter, achieving a 4.9% year-over-year constant currency revenue growth, marking the twelfth consecutive quarter of mid-single-digit gains. Total revenue reached $2.023 billion, driven by robust performances in their Sports, Extremities, and Trauma (S.E.T.) segments, which grew 8.4% year-over-year. Despite challenges from prior ERP disruptions, the company is regaining operational stability, with significant cash flow and share repurchases totaling $870 million for the year.
Looking ahead, Zimmer Biomet projects a 2025 revenue growth of 3% to 5% and adjusted earnings per share (EPS) between $8.15 and $8.35, excluding the impact of the upcoming $1.1 billion Paragon 28 acquisition. This acquisition is expected to enhance their foot and ankle offerings and is projected to be accretive to revenue growth within two years. However, the company anticipates a foreign currency headwind that could dampen reported revenue growth.
For market professionals, the key takeaway is that Zimmer Biomet’s strategic focus on innovation, including over 50 new product launches planned, positions the company for accelerated growth, particularly in the second half of 2025, despite near-term margin pressures.
Source: fool.com